<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051332</url>
  </required_header>
  <id_info>
    <org_study_id>BS-CTL-III</org_study_id>
    <nct_id>NCT05051332</nct_id>
  </id_info>
  <brief_title>Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of Treatment of Articular Cartilage Lesions With CartiLife®</brief_title>
  <official_title>A Multi-Center, Active-Controlled, Open-Label, Phase III Trial to Compare the Efficacy and Safety for Treatment of Autologous Chondrocytes Implantation With CartiLife Versus Microfracture for Patients With Knee Chondral Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosolution Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosolution Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of pellet-type extracellular matrix-associated autologous&#xD;
      chondrocytes (CartiLife®) obtained by cultivating costal chondrocytes of the subject&#xD;
      implanted into articular cartilage defects of the knee resulting from trauma or degeneration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, phase 3 study is being conducted to evaluate the safety and efficacy of&#xD;
      pellet-type extracellular matrix-associated autologous chondrocytes (CartiLife®) compared&#xD;
      with microfracture surgery in adults with articular cartilage defects due to trauma or&#xD;
      degeneration of the knee. It is hypothesized that CartiLife® treatment will demonstrate&#xD;
      structural regeneration and improvement in function and pain at Week 48 compared to baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Investigational Group : CartiLife® Procedure: Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm^3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.&#xD;
Active comparator: Microfracture Surgery Procedure : Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue)</measure>
    <time_frame>At Week 48, post-operation</time_frame>
    <description>MOCART is a validated tool that provides reliable, reproducible, and accurate assessment of cartilage repair tissue (Marlovits et al, 2006 that; Trattnig et al, 2011).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KOOS Total Score</measure>
    <time_frame>From Week 0 to Week 48, post-operation</time_frame>
    <description>The KOOS is a reliable and valid patient-reported outcome measurement tool that evaluates both short-term and long-term consequences of knee injury. The 5 separately scored subscales of Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related QOL may enrich clinical and research data interpretation (Roos and Lohmander, 2003; Collins et al, 2011).&#xD;
In the 'Knee injury and Osteoarthritis Outcome Score', scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MOCART Score</measure>
    <time_frame>At Week 24 and Week 96, post-operation</time_frame>
    <description>MOCART is a validated tool that provides reliable, reproducible, and accurate assessment of cartilage repair tissue (Marlovits et al, 2006 that; Trattnig et al, 2011).&#xD;
In the 'Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) Score', the total score ranges from 0 to 100, with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lysholm Score</measure>
    <time_frame>At Week 0 to Week 8, 24, 48 and 96, post-operation</time_frame>
    <description>The Lysholm scale is a broadly applicable, validated tool for measuring changes following nonsurgical and surgical intervention, as well as deterioration over time in patients with various knee pathologies (Collins et al, 2011).&#xD;
In the 'Lysholm score', the total score ranges from 0 to 100, with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IKDC Score</measure>
    <time_frame>At Week 0 to Week 8, 24, 48 and 96, post-operation</time_frame>
    <description>The IKDC Knee form covers domains likely to be important to patients and has adequate consistency and broad applicability across mixed groups of patients (Collins et al, 2011).&#xD;
In the 'International Knee Documentation Committee Subjective Knee Form', the total score ranges from 0 to 100, with a score of 0 indicating the worst knee symptoms(lowest level of function or highest level of symptoms) and 100 indicating no knee symptoms(highest level of function and lowest level of symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS Score (Pain, Other symptoms, Function in daily living, Function in sport and recreation, and knee-related QOL subscales)</measure>
    <time_frame>At Week 0 to Week 8, 24, 48 and 96, post-operation</time_frame>
    <description>The KOOS is a reliable and valid patient-reported outcome measurement tool that evaluates both short-term and long- term consequences of knee injury. The 5 separately scored subscales of Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related QOL may enrich clinical and research data interpretation (Roos and Lohmander, 2003; Collins et al, 2011).&#xD;
KOOS Score (Pain, Other symptoms, Function in daily living, Function in sport and recreation, and knee-related QOL subscales) are measured between 0, 1, 2, 3 and 4. The KOOS subscales are scored separately: Pain (9 items); Symptoms (7 items); Function in daily living (17 items); Function in sport and recreation (5 items); knee-related QOL (4 items). Each scale is scored between 0 to 4. The total score ranges from 0 to 100, with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (100mm Pain Visual Analogue Scale)</measure>
    <time_frame>At Week 0 to Week 8, 24, 48 and 96, post-operation</time_frame>
    <description>The VAS is a validated, ubiquitous tool for patient-reported measurement of pain at a given point in time (Kersten et al, 2014).&#xD;
Visual Analogue Scale (VAS) is a measurement instrument that measures a specified characteristic which is deemed difficult to quantify across a continuous line of value to determine its representative value. The VAS scale ranges from 0 to 100 mm, with 0 indicating absence of pain and 100 indicating the worst pain experienced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tegner Activity Scale</measure>
    <time_frame>At Week 0 to Week 8, 24, 48 and 96, post-operation</time_frame>
    <description>The Tegner activity score is a frequently used patient-administered activity rating system for patients with various knee activity functions. The instrument scores a person's activity level between 0 and 10 where 0 is 'on sick leave/disability' and 10 is 'participation in competitive sports such as soccer at a national or international elite level' (Karen Hambly, 2011). A level of 0 indicates that the patient is unable to participate in activities barring 'Sick leave or disability pension because of knee problems', and a level of 10 indicates that the patient is capable of participating in activities which at its most intense include 'Competitive sports - soccer, football, rugby at a national elite level'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain medication history</measure>
    <time_frame>At Week 0 to Week 8, 24, 48 and 96, post-operation</time_frame>
    <description>Pain medication history is an indicator of patient pain. Pain medication history is an indicator of patient pain. The frequency of analgesic ingestion is measured for the specified duration over the course of the clinical trial, and changes in analgesic ingestion in terms of frequency are assessed to analyze the efficacy of the clinical trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related adverse events</measure>
    <time_frame>At Week 0 (pre-operation), and up to 24 Months (post-operation)</time_frame>
    <description>Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results. The total number of patients who exhibit symptoms identified as an adverse event will be cumulatively combined to obtain a whole digit number representing the number of patients who have suffered an adverse event throughout the course of the clinical trial.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Articular Cartilage Defect</condition>
  <condition>Articular Cartilage Degeneration</condition>
  <arm_group>
    <arm_group_label>CartiLife®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm^3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microfracture Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous Chondrocyte Implantation (CartiLife®)</intervention_name>
    <description>CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm^3 defect</description>
    <arm_group_label>CartiLife®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microfracture Surgery</intervention_name>
    <description>Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate</description>
    <arm_group_label>Microfracture Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study, an individual must meet all of the&#xD;
        following:&#xD;
&#xD;
          1. Patients over the age of 18.&#xD;
&#xD;
          2. Defect size: 2 to 10 cm^2 on the unilateral knee cartilage (up to 4 ㎤ in volume).&#xD;
&#xD;
          3. Defect: isolated ICRS (International Cartilage Repair Society) grade III or IV single&#xD;
             defect chondral lesion on articular cartilage with comparatively healthy cartilage&#xD;
             present near the lesion site (ICRS Grade 1 ~ 2).&#xD;
&#xD;
          4. Patients with a KOOS total score below 55.&#xD;
&#xD;
          5. Patients able to walk without aid.&#xD;
&#xD;
          6. Patients who agree to abide by rehabilitation protocols and follow-up programs,&#xD;
             including residential exercise routines.&#xD;
&#xD;
          7. Patients who provide written consent to the application of the clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Individuals who meet any of the following will be excluded from participation in this&#xD;
        study:&#xD;
&#xD;
          1. Patients with inflammatory articular diseases such as rheumatoid arthritis or gouty&#xD;
             arthritis.&#xD;
&#xD;
          2. Patients scoring 3 or above on the Kellgren-Lawrence Grading Scale.&#xD;
&#xD;
          3. Patients with inflammatory articular diseases related to autoimmune diseases.&#xD;
&#xD;
          4. Patients hypersensitive to bovine derived proteins or any of the components in this&#xD;
             product.&#xD;
&#xD;
          5. Patients hypersensitive to Gentamycin.&#xD;
&#xD;
          6. Patients with Haemophilia or markedly reduced immune function.&#xD;
&#xD;
          7. Patients with arterial bleeding and severe venous bleeding.&#xD;
&#xD;
          8. Patients with other diseases including tumors except for cartilaginous defects of&#xD;
             joints.&#xD;
&#xD;
          9. Patients with a history of radiation treatment and chemotherapy within the past two&#xD;
             years.&#xD;
&#xD;
         10. Patients who are pregnant, or nursing a baby.&#xD;
&#xD;
         11. Patients who participate in concurrent clinical trials or previous clinical trials&#xD;
             within 30 days of administration.&#xD;
&#xD;
         12. Other cases where the investigator deems the patient ineligible for participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jungsun Lee, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Biosolution Co., Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyoung Ho Yoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung Hee University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Doo Yoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University Mokdong Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Hak Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung Hee University Hospital at Gangdong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung-Hwan Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ji Hoon Bae, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyuk-Soo Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joon Ho Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Min Jung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong In, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic UNIV. of Korea Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chong Bum Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital (1)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong Seuk Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital (2)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seok Jung Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic UNIV. of Korea Uijeongbu St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Geun Seon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong Hwi Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chosun University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-Mo Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seung Joon Rhee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Won Moon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haeundae Paik Hospital, Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Choi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kosin University Gospel Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong Yun Lee, BS</last_name>
    <phone>+82 2 3446 8884</phone>
    <phone_ext>6670</phone_ext>
    <email>white6678@biosolutions.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eunkyung Lee, Ph.D</last_name>
    <phone>+82 2 3446 8884</phone>
    <phone_ext>6621</phone_ext>
    <email>sophia96@biosolutions.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>48108</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Hwa Gong</last_name>
      <phone>+82-51-797-0493</phone>
      <email>velika-jh@nate.com</email>
    </contact>
    <investigator>
      <last_name>Sang Won Moon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49267</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Ram Hong</last_name>
      <email>hbr4162@naver.com</email>
    </contact>
    <investigator>
      <last_name>Young Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su Jin Kang</last_name>
      <email>kkangsujin22@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Young-Mo Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youngye Park</last_name>
      <email>dadosea251@daum.net</email>
    </contact>
    <investigator>
      <last_name>Jong Geun Seon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chosun University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61453</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Bum</last_name>
      <phone>+82-62-220-3141</phone>
      <email>wozl84@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Dong Hwi Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyeonghwa Hyun</last_name>
      <email>dong102877@naver.com</email>
    </contact>
    <investigator>
      <last_name>Seung Joon Rhee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital (1)</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sohyeon Jeon</last_name>
      <phone>+82-31-787-7213</phone>
      <email>sohyeon6762@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chong Bum Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital (2)</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So Hyeon Jeon</last_name>
      <phone>+82-31-787-7209</phone>
      <email>r1258@snubh.org</email>
    </contact>
    <investigator>
      <last_name>Yong Seuk Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chae Hong Lee</last_name>
      <phone>+82-2-958-8374</phone>
      <email>lchh75@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Kyoung Ho Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Jeong Choi</last_name>
      <email>ddw02045@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyuk-Soo Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Mi Yoon</last_name>
      <phone>+82-2-2228-2184</phone>
      <email>esther0123@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Min Jung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seon Jin</last_name>
      <phone>+82-2-440-7775</phone>
      <email>82wjin@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Sang Hak Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06230</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi So Lee</last_name>
      <phone>+82-2-2019-5419</phone>
      <email>mforever486m@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Sung-Hwan Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahreum Kim</last_name>
      <email>01199996757@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Joon Ho Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye Min Choi</last_name>
      <phone>+82-2-2650-2811</phone>
      <email>hyemmmmm@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jae Doo Yoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sookee Son</last_name>
      <email>di0120@naver.com</email>
    </contact>
    <investigator>
      <last_name>Ji Hoon Bae</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic UNIV. of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>16591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeonah Kwon</last_name>
      <phone>+82-2-2258-2838</phone>
      <email>dfg4512@naver.com</email>
    </contact>
    <investigator>
      <last_name>Yong In, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic UNIV. of Korea Uijeongbu St. Mary's Hospital</name>
      <address>
        <city>Uijeongbu-si</city>
        <zip>11765</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyeong-ok Jo</last_name>
      <phone>+82-31-820-3654</phone>
      <email>allofmy0405@naver.com</email>
    </contact>
    <investigator>
      <last_name>Seok Jung Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Yoon KH, Park JY, Lee JY, Lee E, Lee J, Kim SG. Costal Chondrocyte-Derived Pellet-Type Autologous Chondrocyte Implantation for Treatment of Articular Cartilage Defect. Am J Sports Med. 2020 Apr;48(5):1236-1245. doi: 10.1177/0363546520905565. Epub 2020 Mar 3.</citation>
    <PMID>32125878</PMID>
  </reference>
  <reference>
    <citation>Yoon KH, Yoo JD, Choi CH, Lee J, Lee JY, Kim SG, Park JY. Costal Chondrocyte-Derived Pellet-Type Autologous Chondrocyte Implantation versus Microfracture for Repair of Articular Cartilage Defects: A Prospective Randomized Trial. Cartilage. 2020 Jun 1:1947603520921448. doi: 10.1177/1947603520921448. [Epub ahead of print]</citation>
    <PMID>32476445</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are no future plans to share the IPD at this time.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>NCT03545269</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.gov/</doc_url>
      <doc_comment>Study to Assess the Efficacy and Safety of Treatment of Articular Cartilage Lesions With CartiLife®</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>NCT03517046</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.gov/</doc_url>
      <doc_comment>Study to Assess the Safety of Treatment of Articular Cartilage Lesions With CartiLife®</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

